A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

January 26, 2026

Primary Completion Date

May 17, 2030

Study Completion Date

May 17, 2030

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

Ubamatamab

Administered per the protocol

DRUG

REGN7075

Administered per the protocol

DRUG

Sarilumab

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY